124 related articles for article (PubMed ID: 28196745)
1. Development of cell-based assay for predictively evaluating the FcγR-mediated human immune cell activation by therapeutic monoclonal antibodies.
Takakura M; Tada M; Ishii-Watabe A
Biochem Biophys Res Commun; 2017 Mar; 485(1):189-194. PubMed ID: 28196745
[TBL] [Abstract][Full Text] [Related]
2. [Characterization of Therapeutic Monoclonal Antibodies by Using FcγR-expressing Reporter Cell Lines].
Tada M; Ishii-Watabe A
Yakugaku Zasshi; 2017; 137(7):837-843. PubMed ID: 28674297
[TBL] [Abstract][Full Text] [Related]
3. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
Front Immunol; 2019; 10():390. PubMed ID: 30899264
[TBL] [Abstract][Full Text] [Related]
4. Fcγ Receptor Activation by Human Monoclonal Antibody Aggregates.
Tada M; Aoyama M; Ishii-Watabe A
J Pharm Sci; 2020 Jan; 109(1):576-583. PubMed ID: 31676270
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
6. A Cell-Based Reporter Assay Measuring the Activation of Fc Gamma Receptors Induced by Therapeutic Monoclonal Antibodies.
Aoyama M; Tada M; Ishii-Watabe A
Methods Mol Biol; 2019; 1904():423-429. PubMed ID: 30539484
[TBL] [Abstract][Full Text] [Related]
7. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.
Chenoweth AM; Wines BD; Anania JC; Mark Hogarth P
Immunol Cell Biol; 2020 Apr; 98(4):287-304. PubMed ID: 32157732
[TBL] [Abstract][Full Text] [Related]
8. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
9. Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies.
Tada M; Ishii-Watabe A; Suzuki T; Kawasaki N
PLoS One; 2014; 9(4):e95787. PubMed ID: 24752341
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.
Ortiz DF; Lansing JC; Rutitzky L; Kurtagic E; Prod'homme T; Choudhury A; Washburn N; Bhatnagar N; Beneduce C; Holte K; Prenovitz R; Child M; Killough J; Tyler S; Brown J; Nguyen S; Schwab I; Hains M; Meccariello R; Markowitz L; Wang J; Zouaoui R; Simpson A; Schultes B; Capila I; Ling L; Nimmerjahn F; Manning AM; Bosques CJ
Sci Transl Med; 2016 Nov; 8(365):365ra158. PubMed ID: 27856797
[TBL] [Abstract][Full Text] [Related]
11. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
12. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
13. FcgammaR: The key to optimize therapeutic antibodies?
Sibéril S; Dutertre CA; Fridman WH; Teillaud JL
Crit Rev Oncol Hematol; 2007 Apr; 62(1):26-33. PubMed ID: 17240158
[TBL] [Abstract][Full Text] [Related]
14. Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates.
Aoyama M; Tada M; Yokoo H; Demizu Y; Ishii-Watabe A
Pharm Res; 2022 Jan; 39(1):89-103. PubMed ID: 34961908
[TBL] [Abstract][Full Text] [Related]
15. Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro.
Dettke M; Loibner H
Br J Cancer; 2000 Jan; 82(2):441-5. PubMed ID: 10646902
[TBL] [Abstract][Full Text] [Related]
16. A novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptors.
Corrales-Aguilar E; Trilling M; Reinhard H; Mercé-Maldonado E; Widera M; Schaal H; Zimmermann A; Mandelboim O; Hengel H
J Immunol Methods; 2013 Jan; 387(1-2):21-35. PubMed ID: 23023090
[TBL] [Abstract][Full Text] [Related]
17. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.
Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A
Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013
[TBL] [Abstract][Full Text] [Related]
18. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
19. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
20. [Nonclinical Evaluation of Next-generation Therapeutic Monoclonal Antibodies].
Ishii-Watabe A; Tada M; Suzuki T; Kawasaki N
Yakugaku Zasshi; 2015; 135(7):857-66. PubMed ID: 26135085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
